Characteristics of patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and myelodysplastic syndrome where donor/recipient pairs have high-resolution typing for HLA-A, -B, -C, -DRB1, -DQ, and -DP through the NMDP and where recipient received a myeloablative conditioning regimen
| Variable . | 8/8 for HLA-A, -B,-C and -DRB1 n (%) . | 7/8 for HLA-A, -B,-C and -DRB1 n (%) . | <7/8 for HLA-A, -B,-C and -DRB1 n (%) . | P value . |
|---|---|---|---|---|
| Number of patients | 1837 | 985 | 1031 | |
| Number of centers | 105 | 100 | 97 | |
| Age, median (range), y | 35 (<1-65) | 31 (<1-65) | 28 (<1-59) | <.0001 |
| Age at transplant | <.0001 | |||
| ≤20 y | 361 (20) | 271 (27) | 347 (34) | |
| 21–50 y | 1258 (68) | 626 (64) | 633 (61) | |
| >50 y | 217 (12) | 88 (9) | 51 (5) | |
| Race | <.0001 | |||
| White | 1712 (93) | 858 (87) | 768 (74) | |
| Black | 44 (2) | 50 (5) | 95 (9) | |
| Hispanic | 54 (3) | 53 (5) | 113 (11) | |
| Other | 27 (1) | 24 (2) | 54 (5) | |
| Male sex | 1041 (57) | 537 (55) | 605 (59) | .17 |
| Karnofsky prior to transplant > 90 | 1325 (72) | 713 (72) | 750 (73) | .24 |
| HEL matching | <.0001 | |||
| HLA-A, -B, -C and -DRB1 matched | 1837 (100) | 0 | 0 | |
| HLA-A, -B, or -C mismatched only | 0 | 868 (88) | 740 (72) | |
| HLA-DRB1 mismatched only | 0 | 117 (12) | 6 (<1) | |
| Mismatched at DRB1 and at one of HLA-A, -B and/or -C | 0 | 0 | 285 (28) | |
| Number of patients | 1837 | 985 | 1031 | |
| LEL | <.0001 | |||
| DQ, DP, and DRB3/4/5 | ||||
| 6/6 Match | 240 (13) | 99 (10) | 85 (8) | |
| 5/6 Match | 906 (49) | 411 (42) | 364 (35) | |
| 4/6 Match | 583 (32) | 366 (37) | 371 (36) | |
| <4/6 Match | 108 (6) | 109 (11) | 211 (21) | |
| DRB3/4/5 | <.0001 | |||
| Matched | 1709 (93) | 873 (89) | 853 (83) | |
| 1 mismatch | 127 (7) | 110 (11) | 172 (17) | |
| 2 mismatches | 1 (<1) | 2 (<1) | 6 (<1) | |
| DQ | <.0001 | |||
| Matched | 1675 (91) | 795 (81) | 731 (71) | |
| 1 mismatch | 156 (8) | 184 (19) | 274 (27) | |
| 2 mismatches | 6 (<1) | 6 (1) | 26 (2) | |
| DP | .0006 | |||
| Matched | 265 (14) | 126 (13) | 115 (11) | |
| 1 mismatch | 1028 (56) | 535 (54) | 532 (52) | |
| 2 mismatches | 544 (30) | 324 (33) | 384 (37) | |
| Diagnosis | .0002 | |||
| Acute myeloid leukemia | 496 (27) | 294 (30) | 265 (26) | |
| Acute lymphoblastic leukemia | 410 (22) | 253 (26) | 289 (28) | |
| Chronic myeloid leukemia | 756 (41) | 366 (37) | 416 (40) | |
| Myelodysplastic syndrome | 175 (10) | 72 (7) | 61 (6) | |
| Disease status at transplant | .0009 | |||
| Early | 833 (45) | 378 (38) | 389 (38) | |
| Intermediate | 673 (37) | 410 (42) | 448 (43) | |
| Advanced | 327 (18) | 195 (20) | 192 (19) | |
| Other | 4 (<1) | 2 (<1) | 2 (<1) | |
| Conditioning regimen: total body irradiation based | 1490 (81) | 807 (82) | 909 (88) | <.0001 |
| GvHD prophylaxis | <.0001 | |||
| Tacrolimus + (MTX or MMF or steroids) ± other | 365 (20) | 186 (19) | 141 (14) | |
| Tacrolimus ± other | 3 (<1) | 6 (1) | 3 (<1) | |
| CsA + MTX ± other | 1075 (59) | 514 (52) | 554 (54) | |
| CsA ± other (No MTX) | 68 (4) | 30 (3) | 38 (4) | |
| MMF ± other | 4 (<1) | 1 (<1) | 0 | |
| MTX ± other (No CSA) | 13 (1) | 5 (1) | 13 (1) | |
| T-cell depletion | 307 (17) | 241 (24) | 282 (27) | |
| Other | 2 (<1) | 2 (<1) | 0 | |
| Graft type | <.0001 | |||
| Bone marrow | 1695 (92) | 916 (93) | 1000 (97) | |
| PBSC | 142 (8) | 69 (7) | 31 (3) | |
| Donor/recipient sex match | <.0001 | |||
| Male/male | 717 (39) | 331 (34) | 333 (32) | |
| Male/female | 443 (24) | 237 (24) | 214 (21) | |
| Female/male | 324 (18) | 206 (21) | 272 (26) | |
| Female/female | 353 (19) | 211 (21) | 212 (21) | |
| Donor/recipient cytomegalovirus match | .02 | |||
| Negative/negative | 667 (36) | 341 (35) | 305 (30) | |
| Negative/positive | 515 (28) | 266 (27) | 304 (29) | |
| Positive/negative | 297 (16) | 160 (16) | 174 (17) | |
| Positive/positive | 303 (16) | 192 (19) | 218 (21) | |
| Unknown | 55 (3) | 26 (3) | 30 (3) | |
| Donor age, median (range), y | 36 (18-60) | 36 (19-59) | 36 (18-60) | .23 |
| 18-29 | 478 (25) | 243 (25) | 271 (26) | |
| 30-39 | 726 (40) | 376 (38) | 384 (37) | |
| 40-49 | 508 (28) | 284 (29) | 305 (30) | |
| 50 and older | 125 (7) | 82 (8) | 71 (7) | |
| Time from diagnosis to transplant, mo median (range) | 11 (0.3-232) | 13 (0.3-309) | 15 (0.4-200) | <.0001 |
| Year of transplant | <.0001 | |||
| 1988-1993 | 335 (18) | 176 (18) | 282 (27) | |
| 1994-1998 | 753 (41) | 403 (41) | 455 (44) | |
| 1999-2003 | 749 (41) | 406 (41) | 294 (29) | |
| Median follow-up of survivors, mo | 73 (3-194) | 63 (6-191) | 86 (4-192) | .003* |
| Variable . | 8/8 for HLA-A, -B,-C and -DRB1 n (%) . | 7/8 for HLA-A, -B,-C and -DRB1 n (%) . | <7/8 for HLA-A, -B,-C and -DRB1 n (%) . | P value . |
|---|---|---|---|---|
| Number of patients | 1837 | 985 | 1031 | |
| Number of centers | 105 | 100 | 97 | |
| Age, median (range), y | 35 (<1-65) | 31 (<1-65) | 28 (<1-59) | <.0001 |
| Age at transplant | <.0001 | |||
| ≤20 y | 361 (20) | 271 (27) | 347 (34) | |
| 21–50 y | 1258 (68) | 626 (64) | 633 (61) | |
| >50 y | 217 (12) | 88 (9) | 51 (5) | |
| Race | <.0001 | |||
| White | 1712 (93) | 858 (87) | 768 (74) | |
| Black | 44 (2) | 50 (5) | 95 (9) | |
| Hispanic | 54 (3) | 53 (5) | 113 (11) | |
| Other | 27 (1) | 24 (2) | 54 (5) | |
| Male sex | 1041 (57) | 537 (55) | 605 (59) | .17 |
| Karnofsky prior to transplant > 90 | 1325 (72) | 713 (72) | 750 (73) | .24 |
| HEL matching | <.0001 | |||
| HLA-A, -B, -C and -DRB1 matched | 1837 (100) | 0 | 0 | |
| HLA-A, -B, or -C mismatched only | 0 | 868 (88) | 740 (72) | |
| HLA-DRB1 mismatched only | 0 | 117 (12) | 6 (<1) | |
| Mismatched at DRB1 and at one of HLA-A, -B and/or -C | 0 | 0 | 285 (28) | |
| Number of patients | 1837 | 985 | 1031 | |
| LEL | <.0001 | |||
| DQ, DP, and DRB3/4/5 | ||||
| 6/6 Match | 240 (13) | 99 (10) | 85 (8) | |
| 5/6 Match | 906 (49) | 411 (42) | 364 (35) | |
| 4/6 Match | 583 (32) | 366 (37) | 371 (36) | |
| <4/6 Match | 108 (6) | 109 (11) | 211 (21) | |
| DRB3/4/5 | <.0001 | |||
| Matched | 1709 (93) | 873 (89) | 853 (83) | |
| 1 mismatch | 127 (7) | 110 (11) | 172 (17) | |
| 2 mismatches | 1 (<1) | 2 (<1) | 6 (<1) | |
| DQ | <.0001 | |||
| Matched | 1675 (91) | 795 (81) | 731 (71) | |
| 1 mismatch | 156 (8) | 184 (19) | 274 (27) | |
| 2 mismatches | 6 (<1) | 6 (1) | 26 (2) | |
| DP | .0006 | |||
| Matched | 265 (14) | 126 (13) | 115 (11) | |
| 1 mismatch | 1028 (56) | 535 (54) | 532 (52) | |
| 2 mismatches | 544 (30) | 324 (33) | 384 (37) | |
| Diagnosis | .0002 | |||
| Acute myeloid leukemia | 496 (27) | 294 (30) | 265 (26) | |
| Acute lymphoblastic leukemia | 410 (22) | 253 (26) | 289 (28) | |
| Chronic myeloid leukemia | 756 (41) | 366 (37) | 416 (40) | |
| Myelodysplastic syndrome | 175 (10) | 72 (7) | 61 (6) | |
| Disease status at transplant | .0009 | |||
| Early | 833 (45) | 378 (38) | 389 (38) | |
| Intermediate | 673 (37) | 410 (42) | 448 (43) | |
| Advanced | 327 (18) | 195 (20) | 192 (19) | |
| Other | 4 (<1) | 2 (<1) | 2 (<1) | |
| Conditioning regimen: total body irradiation based | 1490 (81) | 807 (82) | 909 (88) | <.0001 |
| GvHD prophylaxis | <.0001 | |||
| Tacrolimus + (MTX or MMF or steroids) ± other | 365 (20) | 186 (19) | 141 (14) | |
| Tacrolimus ± other | 3 (<1) | 6 (1) | 3 (<1) | |
| CsA + MTX ± other | 1075 (59) | 514 (52) | 554 (54) | |
| CsA ± other (No MTX) | 68 (4) | 30 (3) | 38 (4) | |
| MMF ± other | 4 (<1) | 1 (<1) | 0 | |
| MTX ± other (No CSA) | 13 (1) | 5 (1) | 13 (1) | |
| T-cell depletion | 307 (17) | 241 (24) | 282 (27) | |
| Other | 2 (<1) | 2 (<1) | 0 | |
| Graft type | <.0001 | |||
| Bone marrow | 1695 (92) | 916 (93) | 1000 (97) | |
| PBSC | 142 (8) | 69 (7) | 31 (3) | |
| Donor/recipient sex match | <.0001 | |||
| Male/male | 717 (39) | 331 (34) | 333 (32) | |
| Male/female | 443 (24) | 237 (24) | 214 (21) | |
| Female/male | 324 (18) | 206 (21) | 272 (26) | |
| Female/female | 353 (19) | 211 (21) | 212 (21) | |
| Donor/recipient cytomegalovirus match | .02 | |||
| Negative/negative | 667 (36) | 341 (35) | 305 (30) | |
| Negative/positive | 515 (28) | 266 (27) | 304 (29) | |
| Positive/negative | 297 (16) | 160 (16) | 174 (17) | |
| Positive/positive | 303 (16) | 192 (19) | 218 (21) | |
| Unknown | 55 (3) | 26 (3) | 30 (3) | |
| Donor age, median (range), y | 36 (18-60) | 36 (19-59) | 36 (18-60) | .23 |
| 18-29 | 478 (25) | 243 (25) | 271 (26) | |
| 30-39 | 726 (40) | 376 (38) | 384 (37) | |
| 40-49 | 508 (28) | 284 (29) | 305 (30) | |
| 50 and older | 125 (7) | 82 (8) | 71 (7) | |
| Time from diagnosis to transplant, mo median (range) | 11 (0.3-232) | 13 (0.3-309) | 15 (0.4-200) | <.0001 |
| Year of transplant | <.0001 | |||
| 1988-1993 | 335 (18) | 176 (18) | 282 (27) | |
| 1994-1998 | 753 (41) | 403 (41) | 455 (44) | |
| 1999-2003 | 749 (41) | 406 (41) | 294 (29) | |
| Median follow-up of survivors, mo | 73 (3-194) | 63 (6-191) | 86 (4-192) | .003* |
Note: Data are adjusted for the NMDP corrective action plan.4,5
Log-rank P value.